@article{de15b65a2bdb44daa06f8236191c9e45,
title = "Stepwise development of a cancer care delivery research study to evaluate the prevalence of virus infections in cancer patients",
abstract = "Background: SWOG initiated a cancer care delivery research study of virus infection rates among newly diagnosed cancer patients. This study will inform viral screening guidelines in oncology clinics. Methods: In a first step 'vanguard' phase, we evaluated the feasibility of multiple study procedures. Site investigators were surveyed to obtain feedback on study implementation. Results: Much higher enrollment occurred at sites where all physicians participated and viral testing was performed as routine practice. These procedures will be required going forward. Additional protocol changes based on site investigator input were implemented. Conclusion: This multistep protocol design process illustrates how cancer care delivery research studies can adapt to real-world strategies and procedures that exist at community clinics where the predominance of cancer patients are treated.",
keywords = "cancer care delivery research, screening, viral infections in cancer patients",
author = "Unger, {Joseph M.} and Hershman, {Dawn L.} and Arnold, {Kathryn B.} and Rohit Loomba and Rashmi Chugh and Hwang, {Jessica P.} and O'rourke, {Mark A.} and Bhadkamkar, {Nishin A.} and Wang, {Lili X.} and Siegel, {Abby B.} and Cooley, {Timothy P.} and Berenberg, {Jeffrey L.} and Bridges, {Benjamin B.} and Ramsey, {Scott D.}",
note = "Funding Information: This work was supported by the NIH, National Cancer Institute, NCI Community Oncology Research Program (NCORP) Research Base grant 5UG1CA189974-01; and NIH/NCI grants CA189972, CA180858, CA189817, CA189960, CA139519, CA189804, CA189953. The following potential conf licts were reported by the authors. MA O'Rourke reported stock ownership or interest in Novacyt. AB Siegel reported employment by Merck; stock ownership or interest in Merck; research funding support by Exelixis, Bayer / Onyx, Astex and Genentech; and travel /accommodations/expenses by Merck, Bristol-Myers Squibb, Novartis, Merrimack, and Boehringer Ingelheim. SD Ramsey reported consulting or advisory roles with Genentech and Seattle Genetics and research funding support by Bristol- Myers Squibb. R Chugh reported research funding support by Novartis, Mabvax Therapeutics, Morphotek, Lilly and Biomarin. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.",
year = "2016",
month = may,
doi = "10.2217/fon-2015-0076",
language = "English (US)",
volume = "12",
pages = "1219--1231",
journal = "Future Oncology",
issn = "1479-6694",
publisher = "Future Medicine Ltd.",
number = "10",
}